Target in focus: $300, roughly 10% above Johnson & Johnson's recent price near $273 and matching the most bullish Wall Street price target. Bullish case: Accelerating growth in Innovative Medicine, a maturing MedTech pipeline, and a prolonged rally that has lifted shares sharply off their 52-week low.

MRK surged +13.04% to $152.80 on Wednesday, with gains beginning in premarket and accelerating during the regular session. The catalyst: Merck and Moderna announced positive Phase 3 INTerpath-001 results, the first late-stage win for an mRNA cancer vaccine.

Biogen (BIIB) delivered stronger recent performance with a significant Q2 2026 earnings beat and raised full-year guidance, while Pfizer (PFE) trades near 52-week lows ahead of its upcoming earnings. BIIB has posted robust year-to-date and one-year returns compared to PFE’s more modest gains, reflecting differing momentum in the biotechnology and pharmaceutical sectors.

AMGN trades near $385 with upcoming Q2 2026 earnings expected on August 4, following Q1 revenue growth of 6% to $8.6 billion and consistent earnings beats. BIIB closed recently around $203 after reporting Q2 revenue of $2.74 billion (up 3.4% year-over-year) and non-GAAP EPS well above estimates, with mixed stock reactions including gains of nearly 6% on one session.

AMGN and LLY both operate in the biopharmaceutical sector but differ markedly in scale and growth trajectories, with LLY demonstrating significantly higher recent revenue expansion driven by its GLP-1 portfolio. Recent market activity shows AMGN delivering steady single-digit revenue growth and maintaining consistent dividend payouts, while LLY reported 56% year-over-year revenue increase in the first quarter of 2026 alongside upward guidance revisions.

Novo Nordisk beat consensus estimates on both revenue and earnings, with adjusted sales rising 7% at constant exchange rates (CER) to DKK 78.5 billion and adjusted operating profit climbing 11%. The oral Wegovy pill surpassed 5 million cumulative U.S. prescriptions since its January launch, cementing its status as the fastest GLP-1 drug launch by volume in the company's history.

Revenue surged 48% year-over-year to $22.97 billion, crushing the consensus estimate of approximately $20.26 billion by a wide margin. Non-GAAP earnings per share (EPS) reached $8.38 , up 33% from the prior-year period and far exceeding analyst expectations of roughly $6.01, with reported (GAAP) EPS coming in at $7.94.

Eli Lilly shares pulled back roughly 5% from early July all-time highs near $1,249, closing at $1,148.84 on July 31, as investors position ahead of the August 5 Q2 2026 earnings report. The core GLP-1 franchise — Mounjaro and Zepbound — generated $12.82 billion in combined Q1 revenue, about 65% of total sales, and remains the central driver of the investment thesis.

Revenue exceeded expectations: Merck posted second-quarter 2026 sales of $16.6 billion, up 5% year over year and ahead of the $16.41 billion consensus estimate. Non-GAAP EPS beat convincingly: The company reported an adjusted loss of $0.13 per share, significantly better than the $0.27 loss Wall Street had forecast.

Revenue beat: GSK posted second-quarter turnover of £8.41 billion, exceeding the analyst consensus of £8.24 billion and rising 5% at constant exchange rates (CER). Profit outperformance: Core operating profit reached £2.80 billion, ahead of the £2.68 billion consensus, while core earnings per share (EPS) of 50.5 pence comfortably beat the 47.1 pence forecast.

Core EPS beat consensus handsomely: Q2 2026 core earnings per share (EPS) reached $2.63, up 21% year-over-year and well above the company-compiled consensus of $2.49. Revenue landed in line with expectations: Total revenue of $15.38 billion rose 6% from a year ago and matched the $15.39 billion consensus forecast.

Novartis reported Q2 2026 net sales of $14.4 billion, up 3% year-over-year in USD terms. Core earnings per share came in at $2.41, slightly below the prior year but ahead of analyst consensus estimates around $2.16–$2.17.

JNJ delivered strong Q2 2026 results with $25.3 billion in sales and raised full-year guidance, supporting steady performance in a diversified healthcare model. MRNA trades at approximately $68 with significant year-to-date gains exceeding 130%, though it faces expected revenue declines ahead of its July 31 earnings report.

Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, up 6.6% year over year on a reported basis. Adjusted earnings per share reached $2.90, exceeding the consensus estimate of $2.85.

Analysts expect Q2 2026 adjusted EPS of approximately $2.85, up from $2.70 in Q1 2026. Consensus revenue estimate stands near $25.18 billion, reflecting modest year-over-year growth.

Johnson & Johnson shares surged approximately 13.5% over the past 30 days, climbing from $232.16 on June 8 to $263.40 on July 8, 2026, hitting a new 52-week high of $269.43 during the period. A Guggenheim upgrade to $270 with a "Top Pick" designation in large-cap biopharma triggered sharp buying momentum on June 26, accelerating the rally into quarter-end.

Price target in focus: $1,400 represents a widely discussed analyst target and a logical next milestone for Eli Lilly and Company (LLY) , implying roughly 15% upside from recent levels near $1,215. Strongest bullish factors: An industry-leading portfolio of GLP-1 drugs, a historic $27 billion manufacturing expansion, and expanding insurance coverage are creating a powerful revenue flywheel.

Johnson & Johnson shares surged approximately 18% over the last 30 days, climbing from $222.89 on June 2 to $263.04 on July 2, 2026. A Guggenheim analyst upgrade with a $270 price target and a $1 billion Firefly Bio acquisition fueled strong investor optimism around the oncology pipeline.

Eli Lilly shares surged approximately 14.1% over the past 30 days, climbing from $1,064.15 on June 2 to $1,213.91 on July 2, 2026. The rally was fueled by a combination of robust quarterly earnings, raised full-year guidance, and accelerating demand for the company’s GLP-1 obesity and diabetes franchises.

Novo Nordisk (NVO) shares surged approximately 20% over the last 30 days, climbing from $42.00 to $50.43. The broader quarterly performance was even stronger, with the stock gaining roughly 38% since early April.